NR3C2 and obesity due to melanocortin 4 receptor deficiency: Pharmacotherapies targeting RAAS, including ACE inhibitors, angiotensin receptor blockers, mineralocorticoid receptor antagonists (MRAs) or renin inhibitors, may decrease high BP among patients with obesity [12, 13].